Edition:
United States

Bristol-Myers Squibb Co (BMYMP.PK)

BMYMP.PK on OTC Markets Group

885.96USD
12:09pm EST
Change (% chg)

$50.96 (+6.10%)
Prev Close
$835.00
Open
$885.96
Day's High
$885.96
Day's Low
$885.96
Volume
2
Avg. Vol
30
52-wk High
$1,231.90
52-wk Low
$800.00

Latest Key Developments (Source: Significant Developments)

Bristol-Myers squibb and Ono pharmaceutical enters license agreement with Merck
Friday, 20 Jan 2017 04:01pm EST 

Bristol-myers Squibb Co - : Bristol-Myers Squibb and Ono Pharmaceutical Company enter settlement and license agreement with merck to resolve PD-1 antibody patent litigation . Merck to pay Bristol-Myers Squibb and Ono royalties on global sales of keytruda through 2026, and lump-sum payment of $625 million . Agreement will result in dismissal with prejudice of all patent litigation between companies pertaining to keytruda . Agreement ends all global patent-infringement litigation against Merck's sale of keytruda . Merck is also obligated to pay ongoing royalties on global sales of keytruda of 6.5% from Jan 1, 2017 through Dec 31, 2023 . Companies have also granted certain rights to each other under their respective patent portfolios pertaining to PD-1 . Merck is also obligated to pay ongoing royalties on global sales of keytruda 2.5% from January 1, 2024 through Dec 31, 2026 . Royalties pertaining to PD-1 to be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively .Royalties will be shared between Bristol-Myers Squibb and Ono in a 75/25 percent allocation, respectively.  Full Article

Merck announces license agreement resolving Keytruda patent litigation
Friday, 20 Jan 2017 04:01pm EST 

Merck & Co Inc - : Merck announces settlement and license agreement resolving Keytruda® (pembrolizumab) patent litigation . Under settlement and license agreement, company will make a one-time payment of $625 million to Bristol-Myers Squibb . Parties also agreed to dismiss all claims in relevant legal proceedings . $625 million payment will be recorded in company's fourth-quarter and full-year 2016 results . The expense will be excluded from merck's non-gaap results .Parties also agreed to dismiss all claims in relevant legal proceedings..  Full Article

Bristol-Myers sees operating expenses flat through 2020
Tuesday, 10 Jan 2017 12:55pm EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb CEO says expects oncology portfolio to be impacted by competition in 2017, particularly in lung cancer . Bristol-Myers sees potential for pivotal data from 14 trials in 10 tumor types over next 24 months . Bristol-Myers sees operating expenses remaining at 2016 level of about $9 billion through 2020 .Bristol-Myers CEO says business development remains key component of research and development strategy - JP Morgan Healthcare Conference.  Full Article

Bristol-Myers, Calithera Biosciences collaborate to test opdivo along with CB-839
Wednesday, 21 Dec 2016 06:59am EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb and Calithera Biosciences announce clinical collaboration to evaluate opdivo (nivolumab) in combination with CB-839 in clear cell renal cell carcinoma .Bristol-Myers Squibb Co says study to evaluate potential of CB-839 plus opdivo to target immune-suppressive cells in tumor microenvironment.  Full Article

Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics for NG-348
Tuesday, 20 Dec 2016 06:59am EST 

Bristol-Myers Squibb Co : Bristol-Myers Squibb signs exclusive worldwide license agreement with Psioxus Therapeutics for NG-348, an "armed" oncolytic virus to address solid tumors . Bristol-Myers Squibb Co says Psioxus eligible to receive up to $886 million in development and sales-based milestones, as well as royalties on net sales . Bristol-Myers Squibb Co says Psioxus is also eligible to receive up to $886 million in development, regulatory and sales-based milestones, as well as royalties on net sale . Under terms of agreement, Bristol-Myers Squibb will grant Psioxus a $50 million upfront payment .Bristol-Myers Squibb Co says will also be responsible for providing Psioxus funding to support activities related to preclinical development of NG-348.  Full Article

Bristol-Myers Squibb reports dividend increase
Thursday, 8 Dec 2016 04:15pm EST 

Bristol-myers Squibb Co : Bristol-Myers Squibb announces dividend increase . Bristol-Myers Squibb Co - declared an increase of 2.6 pct percent in company's quarterly dividend, beginning in Q1 of 2017. .Bristol-Myers Squibb Co - dividend increase will result in a quarterly dividend of $0.39 per share on $.10 par value common stock of corporation.  Full Article

Transgene announces phase 2 trial with Bristol-Myers Squibb for 2nd line treatment of metastatic non-small cell lung cancer
Wednesday, 7 Dec 2016 11:45am EST 

Transgene SA : Transgene: UC Davis to conduct phase 2 trial of the combination of TG4010 with Opdivo® (nivolumab) for 2nd line treatment of metastatic non-small cell lung cancer (nsclc) .This trial is supported by Transgene through financial support and supply of TG4010 and by Bristol-Myers Squibb through supply of nivolumab for use in clinical study.  Full Article

Bristol-Myers provides positive results from Phase 1/2 study Checkmate-032
Tuesday, 6 Dec 2016 09:16am EST 

Bristol-myers Squibb Co : Press release - opdivo (nivolumab) alone or combined with yervoy (ipilimumab) shows encouraging response and survival rates in recurrent small cell lung cancer, from Phase 1/2 study checkmate -032 . Bristol-Myers Squibb Co - objective response rate with opdivo plus yervoy was 25 pct and was 11 pct with Opdivo monotherapy . Bristol-Myers Squibb Co - estimated two-year survival rate with combination was 30 pct and was 17 pct with opdivo monotherapy . Bristol-Myers Squibb Co - confirmed ORR was 25 pct in patients who received opdivo plus yervoy, was 11 pct with opdivo alone with additional follow-up . Bristol-Myers Squibb Co - grade 3/4 treatment-related discontinuation rates were 10 pct in opdivo plus yervoy group and 4 pct in opdivo group . Bristol-Myers Squibb Co - no new safety signals were observed with opdivo and opdivo plus yervoy in updated analysis . Bristol-Myers Squibb Co - in combination arm, three patients experienced a complete response .Bristol-Myers Squibb-additional efficacy findings included confirmed partial response in 21 patients in opdivo-yervoy arm, 11 patients in opdivo-only arm.  Full Article

Heat Biologics presents topline results from lung cancer drug study
Tuesday, 6 Dec 2016 08:20am EST 

Heat Biologics Inc : Heat Biologics presents topline hs-110/nivolumab combination lung cancer results . Heat Biologics Inc - overall survival compares favorably with single-agent nivolumab . Heat biologics - there were no additional toxicities seen in hs-110/nivolumab combination compared to existing data on single agent nivolumab alone . Heat Biologics Inc - patients who responded best to combination therapy had longer overall survival, better orr than non-immune responders .Heat Biologics - 1-year results from first eight trial patients showed hs-110/nivolumab combination was well-tolerated.  Full Article

Bristol-Myers' Opdivo gets European Commission approval for relapsed or refractory CHL treatment
Tuesday, 22 Nov 2016 03:00pm EST 

Bristol-Myers Squibb Co : European Commission approves Bristol-Myers Squibb's Opdivo (nivolumab) for the treatment of adult patients with relapsed or refractory classical hodgkin lymphoma after autologous stem cell transplant and treatment with brentuximab vedotin .Approval allows for expanded marketing of Opdivo in relapsed or refractory CHL in all 28 member states of EU.  Full Article

Merck, Bristol-Myers agree to settle Keytruda patent suit

Merck & Co said it agreed to enter into a settlement and license agreement with Bristol-Myers Squibb Co and Ono Pharmaceutical Co Ltd to resolve all global patent-infringement litigation related to its cancer drug, Keytruda.